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Introduction {#phy213183-sec-0001}
============

The prevalence of obesity is increasing worldwide, representing an important public health problem (Finucane et al. [2011](#phy213183-bib-0007){ref-type="ref"}). Obesity increases morbidity and mortality, largely attributed to increased incidence of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) (Zimmet et al. [2001](#phy213183-bib-0046){ref-type="ref"}; Li et al. [2006](#phy213183-bib-0023){ref-type="ref"}), which have insulin resistance as a common and important risk factor (Saltiel and Kahn [2001](#phy213183-bib-0035){ref-type="ref"}; Olefsky and Glass [2010](#phy213183-bib-0027){ref-type="ref"}; Nolan et al. [2011](#phy213183-bib-0026){ref-type="ref"}; Fu et al. [2012](#phy213183-bib-0008){ref-type="ref"}).

Physical exercise substantially increases insulin sensitivity and represents one of the most important options to prevent and treat obesity. In the last decade, much attention has been paid to myokines produced and released from the skeletal muscle, which may play a role to increase in insulin sensitivity during and after physical exercise (Pedersen et al. [2007](#phy213183-bib-0031){ref-type="ref"}; Pedersen and Febbraio [2012](#phy213183-bib-0030){ref-type="ref"}). Moreover, an altered pattern of adipokine secretion from expanded and inflamed adipose tissue may be important for the regulation of insulin sensitivity in different tissues (Ouchi et al. [2011](#phy213183-bib-0028){ref-type="ref"}; Turer and Scherer [2012](#phy213183-bib-0044){ref-type="ref"}). Furthermore, physical exercise seems to reduce adipose tissue inflammation and reverse the dysregulation of several adipokines (Lee et al. [2016](#phy213183-bib-0022){ref-type="ref"}). In addition to muscle and fat tissue, the liver plays an important role in regulation of whole body insulin sensitivity. Several hepatokines may affect glucose and lipid metabolism and thereby the risk of developing T2DM and CVD (Stefan and Haring [2013b](#phy213183-bib-0039){ref-type="ref"}; Jung et al. [2016](#phy213183-bib-0017){ref-type="ref"}). However, it remains largely unknown if the beneficial effects of physical exercise can be explained by altered secretion of hepatokines.

Recently, much attention has been focused on fetuin‐A, which might be one of the most important hepatokines regulating human metabolism (Pal et al. [2012](#phy213183-bib-0029){ref-type="ref"}; Stefan and Haring [2013a](#phy213183-bib-0038){ref-type="ref"},[b](#phy213183-bib-0039){ref-type="ref"}). Fetuin‐A is a secretory glycoprotein produced in the liver, and it is a natural inhibitor of the insulin receptor tyrosine kinase in the liver as well as in the skeletal muscle (Auberger et al. [1989](#phy213183-bib-0001){ref-type="ref"}). Fetuin‐A serves as an adaptor protein for saturated fatty acid‐mediated activation of Toll‐like receptor 4 (TLR4) (Pal et al. [2012](#phy213183-bib-0029){ref-type="ref"}). The fetuin‐A‐fatty acid complex is particularly interesting because it might be a potential driving force behind T2DM and CVD by inducing inflammatory signaling and insulin resistance in adipose tissue (Pal et al. [2012](#phy213183-bib-0029){ref-type="ref"}). Fetuin‐A might also induce insulin resistance by itself, as well as together with FFAs, at least according to studies on overfeeding in humans (Samocha‐Bonet et al. [2014](#phy213183-bib-0036){ref-type="ref"}). Obese human participants with T2DM have increased levels of fetuin‐A in blood and increased adipose tissue expression of proinflammatory cytokines (Pal et al. [2012](#phy213183-bib-0029){ref-type="ref"}). Interestingly, free fatty acids (FFAs) may enhance increase proinflammatory cytokine expression and insulin resistance only in the presence of fetuin‐A in human adipocytes in vitro (Pal et al. [2012](#phy213183-bib-0029){ref-type="ref"}). Furthermore, this interaction is supported by human in vivo studies (Stefan and Haring [2013a](#phy213183-bib-0038){ref-type="ref"}). It has been proposed that fetuin‐A is the missing link in lipid‐induced inflammation (Heinrichsdorff and Olefsky [2012](#phy213183-bib-0010){ref-type="ref"}).

In our present study, we examine the effect of an interaction calculated statistically between plasma concentration of FFAs and fetuin‐A on insulin sensitivity after 12 weeks of physical exercise intervention (Langleite et al. [2016](#phy213183-bib-0021){ref-type="ref"}).

Materials and Methods {#phy213183-sec-0002}
=====================

Extensive details regarding the MyoGlu study are published elsewhere (Langleite et al. [2016](#phy213183-bib-0021){ref-type="ref"}).

Ethical approval {#phy213183-sec-0003}
----------------

The study adhered to the Declaration of Helsinki and was approved by the National Regional Committee for Medical and Health Research Ethics North, Tromsø, Oslo, Norway. The study was registered with the US National Library of Medicine Clinical Trials registry (NCT01803568). Written informed consent was obtained from all participants prior to any study‐related procedure.

Participants and exercise intervention {#phy213183-sec-0004}
--------------------------------------

Twenty‐six sedentary men were originally included in the study. Thirteen were classified as normoglycemic, normal weight controls and another 13 as dysglycemic, overweight. The criteria for these classifications were as follows: F‐glucose \<5.6 mmol/L and 2‐h glucose \<7.8 mmol/L and BMI 19--25 or F‐glucose ≥5.6 mmol/L and/or 2‐h glucose ≥7.8 mmol/L and BMI 27--32 (Langleite et al. [2016](#phy213183-bib-0021){ref-type="ref"}).

Four participants differed slightly from these predefined criteria, but the conclusions were similar irrespective of using 26 or 22 participants. The *P‐*value for the interaction effect between plasma fetuin‐A and FFAs levels with GIR increased with fewer data points, but the trend remained the same (*P *\<* *0.1).

Exclusion criteria in this study were known hypertension, liver or kidney disease, chronic inflammatory disease, or any medication expected to affect glucose metabolism (lipid lowering, antihypertensive, ASA, corticosteroids, etc.).

The participants underwent combined resistance and endurance exercise for 12 weeks, including two endurance bicycle sessions (60 min) and two whole body resistance‐training sessions (60 min) per week. The exercise was strictly supervised and the participants were informed not to change their diet. The diet was monitored using food frequency questionnaires before as well as after the exercise intervention (Langleite et al. [2016](#phy213183-bib-0021){ref-type="ref"}).

Insulin sensitivity {#phy213183-sec-0005}
-------------------

The euglycemic‐hyperinsulinemic clamp was performed after an overnight fast, a fixed dose of insulin 40 mU/m^2^ min^−1^ was infused, and glucose 200 mg/mL was adjusted to maintain plasma glucose levels at 5.0 mmol/L for 150 min (euglycemia) (DeFronzo et al. [1979](#phy213183-bib-0005){ref-type="ref"}). Insulin sensitivity is reported as glucose infusion rate relative to body weight (mg/kg/min) and relative to fat free mass (mg/FFM/min) during the last 30 min of the clamp. Full blood glucose concentration was measured by a glucose oxidase method (YSI 2300, Yellow Springs, OH), and plasma glucose concentration was calculated (full blood glucose × 1.119). The products of fasting plasma concentration of insulin and FFAs levels were calculated as an indicator of adipose tissue insulin resistance.

The participants refrained from physical exercise and alcohol for 2 or 3 days before pretests and posttests, respectively. Thus, the training sessions, clamp tests and biopsy samplings did not interfere with each other, and were performed under similar conditions at different days before as well as after the intervention.

Blood and tissue sampling {#phy213183-sec-0006}
-------------------------

Blood (*n *=* *26), muscle (*n *=* *26) and subcutaneous adipose (*n *=* *24, two participants in the dysglycemic, overweight group did not donate adipose tissue biopsies) tissue samples were taken before as well as after 12 weeks intervention (Langleite et al. [2016](#phy213183-bib-0021){ref-type="ref"}). Muscle biopsies were taken from m. vastus lateralis, subcutaneous adipose tissue biopsies were taken from the periumbilical area, and blood sampling was performed by standard antecubital venous puncture. Serum and EDTA‐added plasma samples were stored at −80°C until analyzed.

Biopsies from m. vastus lateralis were immediately transferred to RNA‐later (Qiagen, Limburg, Netherland), kept overnight at 4°C, and transferred to −80°C. Subcutaneous adipose biopsies were immediately frozen in liquid nitrogen and stored at −80°C until further processing.

Plasma levels of fetuin‐A (Catalog \# DFTA00, R&D, MN) were measured in duplicates using enzyme‐linked immunosorbent assays (ELISA) according to the manufacture\'s protocols. Optical density was determined using a microplate reader (Titertec Multiscan Plus; EFLAB, Helsinki, Finland), set to 450 or 490 nm depending on the actual protocols. Standard curves were generated using best‐fit curves.

Free fatty acid levels were determined using a MAXMAT PL multianalyzer (MAXMAT SA, Montpellier, France) with relevant reagents (ref \# D07940/D07950, DIALAB, Wiener Neudorf, Austria).

Tissue RNA isolation and cDNA synthesis {#phy213183-sec-0007}
---------------------------------------

Frozen biopsies were cooled in liquid nitrogen and crushed by a pestle to powder in a liquid nitrogen‐cooled mortar. Tissue powder was then transferred into 1 mL QIAzol Lysis Reagent (Qiagen), and homogenized using TissueRuptor (Qiagen) at full speed for 15 sec, twice. Total RNA was isolated from the homogenate using a miRNeasy Mini Kit (Qiagen). RNA integrity and concentration were determined using Agilent RNA 6000 Nano Chips on a Bioanalyzer 2100 (Agilent Technologies Inc, Santa Clara, CA). Using a high‐capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City CA), 200 ng of total RNA was converted to cDNA for TaqMan real‐time RT‐PCR.

RNA sequencing {#phy213183-sec-0008}
--------------

Indexed sequencing libraries were prepared from RNA from all muscle and adipose tissue samples and deep‐sequenced using the Illumina HiSeq 2000 system (Illumina, San Diego, CA). Illumina HiSeq RTA (real‐time analysis) v1.17.21.3 was used for real‐time analysis during the sequencing. Reads passing Illumina\'s recommended parameters were demultiplexed using CASAVA v1.8.2. For prealignment quality checks, we used the software FastQC v0.10.1. The mean library size was \~44 millions unstranded single‐ended reads for muscle tissue and \~55 millions for adipose tissue with no difference between groups or time points. No batch effects were observed. cDNA sequenced reads alignment was done using Tophat v2.0.8, Samtools v0.1.18, and Bowtie v2.1.0 with default settings against the UCSC hg19 annotated transcriptome and genome dated 14 May 2013. Postalignment quality controls were performed using the Integrative Genome Viewer v2.3 and BEDtools v2.19.1. Reads counted by gene feature were performed by featureCounts in Rsubread 1.14.2 and presented as reads per kilobase of transcript per million mapped reads (RPKM).

Liver fat measurements using magnetic resonance spectroscopy {#phy213183-sec-0009}
------------------------------------------------------------

Lipid and water content in the liver were sampled using three Single Voxel Proton Spectroscopy acquisitions. The lipid fractions were presented as arbitrary units (AU) based on measured amplitudes of lipid and water signals. The jMRUI software package (<http://www.jmrui.eu>) was used to analyze single voxel spectroscopy data. Time‐domain quantification of 1H short echo time signals was used for peak fitting. The water peak, sampled in a water phantom with the applied PRESS sequence, and the lipid peak, created a two‐peak basis set. This was modeled as a single peak using the jMRUI simulation tool (<http://www.jmrui.eu>). Soft constraints on frequency and dampening was used to fit the peaks. The lipid fraction (*f*) was calculated from the formula; *f *= *Al*(*Al *+ *Aw*)*,* where *Al* and *Aw* denotes the fitted amplitude of the lipid and water signals, respectively.

Statistical analyses {#phy213183-sec-0010}
--------------------

Baseline characteristics and the effect of exercise were modeled using linear regression (Table [1](#phy213183-tbl-0001){ref-type="table-wrap"}). The included terms were the parameter tested as dependent variable and participants, due to repeated measures, and time point (baseline and 12 weeks) as independent variables. The formulas used were: parameter \~ group for group differences and parameter \~ participants + time point for exercise effects, corrected for repeated measures. The tilde (\~) and plus (+) are Wilkinson‐Rogers symbolic description of factorial models for analysis of variance (ANOVA). To compare whether the changes in response to exercise differed between the groups, we compared delta values (12 weeks minus baseline values). These models also included baseline values as a covariate to correct for differences at baseline (Table [1](#phy213183-tbl-0001){ref-type="table-wrap"}).

###### 

Participant characteristics at baseline and responses to exercise[a](#phy213183-note-0004){ref-type="fn"}

                                                           Control         Dysglycemics                                                                                                     
  -------------------------------------------------------- --------------- ------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------------------------------------------------
  *n* (men)                                                13                                                                      13                                                       
  Age (y)                                                  49.8 ± 2.1                                                              52.5 ± 1.6                                               
  HbA1c (%)                                                5.2 ± 0.1                                                               5.5 ± 0.1[c](#phy213183-note-0006){ref-type="fn"}        
  Systolic BP (mmHg)                                       128.7 ± 3.3                                                             132.3 ± 2.4                                              
  Diastolic BP (mmHg)                                      73.5 ± 2.3                                                              81.9 ± 2.7[c](#phy213183-note-0006){ref-type="fn"}       
  BMI (kg/h^2^)                                            23.5 ± 0.5      0.0 ± 0.1                                               29.0 ± 0.7[c](#phy213183-note-0006){ref-type="fn"}       −0.4 ± 0.3
  Weight (kg)                                              78.5 ± 2.3      −0.3 ± 0.4                                              95.4 ± 2.8[c](#phy213183-note-0006){ref-type="fn"}       −1.7 ± 0.6[d](#phy213183-note-0007){ref-type="fn"}
  fP‐insulin (pmol/L)                                      38.5 ± 5.2      0.2 ± 5.6                                               65.3 ± 7.5[c](#phy213183-note-0006){ref-type="fn"}       11.7 ± 7.8[e](#phy213183-note-0008){ref-type="fn"}
  fP‐glucose (mmol/L)                                      5.0 ± 0.1       0.2 ± 0.1[d](#phy213183-note-0007){ref-type="fn"}       5.8 ± 0.1[c](#phy213183-note-0006){ref-type="fn"}        0.1 ± 0.1
  GIR (mg/kg/min)                                          7.6 ± 0.4       2.7 ± 0.6[d](#phy213183-note-0007){ref-type="fn"}       4.2 ± 0.5[c](#phy213183-note-0006){ref-type="fn"}        1.2 ± 0.3[d](#phy213183-note-0007){ref-type="fn"}
  GIR (mg/FFM/min)                                         9.4 ± 0.5       3.4 ± 0.7[d](#phy213183-note-0007){ref-type="fn"}       5.7 ± 0.7[c](#phy213183-note-0006){ref-type="fn"}        1.6 ± 0.4[d](#phy213183-note-0007){ref-type="fn"}
  GIR (mmol/m^2^/min)                                      1659.2 ± 94.5   601.9 ± 123.7[d](#phy213183-note-0007){ref-type="fn"}   1004.2 ± 113.0[c](#phy213183-note-0006){ref-type="fn"}   283.3 ± 76.9[d](#phy213183-note-0007){ref-type="fn"}
  Clamp‐insulin (pmol/L)                                   443.9 ± 36.6    6.6 ± 23.6                                              455.5 ± 20.2                                             56.3 ± 24.5[d](#phy213183-note-0007){ref-type="fn"}
  fP‐ALAT (U/L)                                            24.7 ± 2.2      −1.1 ± 1.4                                              44.8 ± 6.8[c](#phy213183-note-0006){ref-type="fn"}       −11.7 ± 5.0[d](#phy213183-note-0007){ref-type="fn"}
  fP‐ASAT (U/L)                                            18.2 ± 1.8      0.3 ± 1.0                                               24.2 ± 4.2                                               −6.2 ± 2.7[d](#phy213183-note-0007){ref-type="fn"} ^,^ [e](#phy213183-note-0008){ref-type="fn"}
  Liver fat (AU)[b](#phy213183-note-0005){ref-type="fn"}   2.8 ± 0.6       −2.8 ± 0.6[d](#phy213183-note-0007){ref-type="fn"}      9.1 ± 1.6[c](#phy213183-note-0006){ref-type="fn"}        −2.7 ± 0.7[d](#phy213183-note-0007){ref-type="fn"} ^,^ [e](#phy213183-note-0008){ref-type="fn"}
  fP‐hsCRP (mg/L)                                          1.0 ± 0.2       0.3 ± 0.3                                               2.8 ± 0.9                                                −0.8 ± 0.7
  fP‐Fetuin‐A (ng/L)                                       445.8 ± 31.4    −54.1 ± 20.0[d](#phy213183-note-0007){ref-type="fn"}    491.6 ± 40.2                                             −44.5 ± 11.1[d](#phy213183-note-0007){ref-type="fn"}
  fP‐FFA (mmol/L)                                          25.5 ± 4.0      −8.6 ± 3.9[d](#phy213183-note-0007){ref-type="fn"}      22.3 ± 2.2                                               0.5 ± 2.9[e](#phy213183-note-0008){ref-type="fn"}

Control; normal weight, normoglycemic men. Dysglycemics; overweight, dysglycemic men. fP, fasting blood plasma; FFA, free fatty acids; BP, blood pressure; ALAT, alanine transaminase; ASAT, aspartate transaminase; hsCRP, high‐sensitivity C‐reactive protein; GIR, glucose infusion rate. Open cells indicates values not available postintervention. Clamp‐insulin was measured as the average of three measurements during steady‐state of the clamp test.

All comparisons were made using linear regression.

*n *=* *10 dysglycemic men.

*P *≤* *0.05 compared to control.

*P *≤* *0.05 compared to baseline.

*P *≤* *0.05 compared to the change in the control group, corrected for differences at baseline.

John Wiley & Sons, Ltd

The second linear regression models were constructed to test the effect of changes in circulating plasma concentrations of fetuin‐A and FFAs, and their interaction, on changes of insulin sensitivity (Table [2](#phy213183-tbl-0002){ref-type="table-wrap"}). The included terms were insulin sensitivity as dependent variable and participants, group allocation, plasma fetuin‐A and FFAs concentration levels as independent variables. The group variable was included to correct for several differences between the groups (Table [1](#phy213183-tbl-0001){ref-type="table-wrap"}), instead of correcting all differing variables separately, to maximize the degrees of freedom in the models. The formula used to investigate the separate effect of plasma concentration of fetuin‐A or FFAs on insulin sensitivity was insulin sensitivity \~ participant + group + fetuin‐A (or FFAs), which predicted changes in insulin sensitivity as a function of changes in plasma fetuin‐A levels (or plasma FFAs levels). To test for interaction effects between changes in plasma concentrations of fetuin‐A and FFAs on changes in insulin sensitivity, we used the formula: insulin sensitivity \~ participant + group + fetuin‐A\*FFAs. The latter variable (interaction between fetuin‐A and FFAs) was the term of interest, representing the fetuin‐A‐FFAs complex (Pal et al. [2012](#phy213183-bib-0029){ref-type="ref"}; Stefan and Haring [2013a](#phy213183-bib-0038){ref-type="ref"}). The same models were subsequently rerun substituting plasma concentrations of fetuin‐A levels with plasma concentrations of total adiponectin, high molecular weight adiponectin or leptin, to test if the interaction effect between fetuin‐A and FFAs were unique.

###### 

Relationships between plasma concentrations of fetuin‐A and FFAs, and their interaction, with insulin sensitivity

                                                  GIR (mg/kg/min)   GIR (mg/FFM/min)   GIR (mmol/m^2^/min)                                
  ----------------------------------------------- ----------------- ------------------ --------------------- ------- -------------------- -------
  Fetuin‐A                                                                                                                                
  (Intercept)                                     3.166 ± 0.539     0.000              3.894 ± 0.683         0.000   694.564 ± 122.712    0.000
  Group[b](#phy213183-note-0011){ref-type="fn"}   −1.598 ± 0.632    0.019              −1.819 ± 0.800        0.033   −335.077 ± 143.840   0.029
  Fetuin‐A                                        0.008 ± 0.006     0.177              0.010 ± 0.007         0.173   1.713 ± 1.279        0.194
  FFAs                                                                                                                                    
  (Intercept)                                     2.773 ± 0.521     0.000              3.384 ± 0.661         0.000   608.882 ± 118.309    0.000
  Group                                           −1.554 ± 0.702    0.037              −1.756 ± 0.890        0.061   −325.948 ± 159.317   0.052
  FFAs                                            0.348 ± 2.769     0.901              0.364 ± 3.512         0.918   81.271 ± 628.860     0.898
  Fetuin‐A\*FFAs                                                                                                                          
  (Intercept)                                     3.348 ± 0.562     0.000              4.118 ± 0.711         0.000   736.183 ± 127.472    0.000
  Group                                           −1.937 ± 0.645    0.007              −2.244 ± 0.817        0.012   −413.011 ± 146.392   0.010
  Fetuin‐A                                        0.006 ± 0.005     0.311              0.007 ± 0.007         0.306   1.196 ± 1.221        0.338
  FFAs                                            −3.953 ± 3.230    0.234              −5.113 ± 4.088        0.225   −917.417 ± 732.889   0.224
  Fetuin‐ A:FFAs                                  −0.182 ± 0.080    0.032              −0.232 ± 0.101        0.031   −42.160 ± 18.073     0.030

GIR; glucose infusion rate.

SE; standard error.

Dysglycemic, overweight men.

John Wiley & Sons, Ltd

The third regression models were constructed to test the effect of changes in plasma concentrations of fetuin‐A and FFAs, and their interaction, on changes in TLR‐ or insulin‐signaling in adipose tissue and skeletal muscle (Tables [3](#phy213183-tbl-0003){ref-type="table-wrap"}, [4](#phy213183-tbl-0004){ref-type="table-wrap"}). The formulas used were either gene \~ participants + group + fetuin‐A (or FFAs) for simple effects, or gene \~ participants + group + fetuin‐A \*FFAs for interaction effects. "Gene" represents a gene annotated in the Kyoto Encyclopedia of Genes and Genomes (KEGG), Biocarta or Reactome TLR‐ and insulin‐signaling pathways (<http://software.broadinstitute.org/gsea/msigdb/>). The number of significantly correlated genes with a parameter was compared to the total number of genes in the pathway using a hypergeometric distribution, whereby we tested if the number of overlapping genes were significantly larger than expected by chance. More details are presented in the legend to Tables [3](#phy213183-tbl-0003){ref-type="table-wrap"}, [4](#phy213183-tbl-0004){ref-type="table-wrap"}.

###### 

TLR‐signaling pathways in adipose tissue may be related to plasma concentration of fetuin‐A and FFAs, and their interaction[a](#phy213183-note-0013){ref-type="fn"}

                               K     k    k/K    *n*    *P‐*value
  ---------------------------- ----- ---- ------ ------ -----------
  Fetuin‐A                                              
  TLR‐signaling                118   20   0.17   1663   \<0.001
  Insulin receptor signaling   108   6    0.06   1663   0.777
  FFAs                                                  
  TLR‐signaling                118   3    0.03   851    0.800
  Insulin receptor signaling   108   4    0.04   851    0.546
  Fetuin‐A\*FFAs                                        
  TLR‐signaling                118   10   0.09   1089   0.045
  Insulin receptor signaling   108   5    0.05   1089   0.557

The *P‐*values were calculated from a hypergeometric distribution (k‐1, K, N‐K, n) where K, genes in gene set; k, genes in overlap; N, total number of genes tested (23.710); and n, total number of genes predicted by the model. The actual genes present in the overlaps (k) are presented in Figure [2](#phy213183-fig-0002){ref-type="fig"}.

Reactome, Biocarta and KEGG pathways for toll‐like receptor (TLR) and insulin receptor signaling were merged into one gene set for TLR and insulin receptor signaling, respectively.

John Wiley & Sons, Ltd

###### 

Insulin receptor signaling in skeletal muscle may be related to plasma concentration of fetuin‐A levels[a](#phy213183-note-0015){ref-type="fn"}

                               K     k    k/K    *n*    *P‐*value
  ---------------------------- ----- ---- ------ ------ -----------
  Fetuin‐A                                              
  TLR‐signaling                118   20   0.09   1430   0.099
  Insulin receptor signaling   108   15   0.14   1430   0.002
  FFAs                                                  
  TLR‐signaling                118   2    0.02   604    0.806
  Insulin receptor signaling   108   1    0.01   604    0.939
  Fetuin‐A\*FFAs                                        
  TLR‐signaling                118   7    0.06   1291   0.465
  Insulin receptor signaling   108   4    0.04   1291   0.846

The *P‐*values were calculated from a hypergeometric distribution (k‐1, K, N‐K, n) where K, genes in gene set; k, genes in overlap; *N*, total number of genes tested (23.710); and n: total number of genes predicted by the model. The actual genes present in the overlaps (k) are shown in Figure [3](#phy213183-fig-0003){ref-type="fig"}.

Reactome, Biocarta, and Kegg pathways for TLR and insulin receptor signaling were merged into one gene set for TLR and insulin receptor signaling, respectively.

John Wiley & Sons, Ltd

The final regression models (Table [6](#phy213183-tbl-0006){ref-type="table-wrap"}) were constructed to test the effect of changes in circulating fetuin‐A and FFAs levels, and their interaction, on changes in gene markers of adipose tissue macrophages. The formulas used were marker \~ participants + group + fetuin‐A (or FFAs) for simple effects, and marker \~ participants + group + fetuin‐A \*FFAs for interaction effects. "Marker" denotes the mean expression of several validated macrophage markers; macrophages in general, the M1‐like and M2‐like phenotype. The list of macrophage‐specific markers is presented in Table [5](#phy213183-tbl-0005){ref-type="table-wrap"} and were obtained from previous studies of human adipose tissue (Capel et al. [2009](#phy213183-bib-0003){ref-type="ref"}; Ahlin et al. [2013](#phy213183-bib-0034){ref-type="ref"}) or based on the frequency of use in the literature (Hill et al. [2014](#phy213183-bib-0012){ref-type="ref"}). We previously evaluated the specificity of these markers, both the individual expressions and the mean expressions, by running comparisons in several white blood cell types (Lee et al. [2016](#phy213183-bib-0022){ref-type="ref"}).

###### 

mRNA markers of macrophages in human adipose tissue based on previously published data (Capel et al. [2009](#phy213183-bib-0003){ref-type="ref"}; Ahlin et al. [2013](#phy213183-bib-0034){ref-type="ref"}; Hill et al. [2014](#phy213183-bib-0012){ref-type="ref"})

  Markers                                      Symbol    Description                                  Study
  -------------------------------------------- --------- -------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  Ma[a](#phy213183-note-0016){ref-type="fn"}   ACP5      Acid phosphatase 5, tartrate resistant       (Capel et al. [2009](#phy213183-bib-0003){ref-type="ref"}; Ahlin et al. [2013](#phy213183-bib-0034){ref-type="ref"})
                                               CCL22     C‐C motif chemokine ligand 22                
                                               CD68      CD68 molecule                                
                                               CD163     CD163 molecule                               
                                               CHIT1     Chitinase 1                                  
                                               CRABP2    Cellular retinoic acid‐binding protein 2     
                                               CSF1R     Colony‐stimulating factor 1 receptor         
                                               GLA       Galactosidase alpha                          
                                               GM2A      GM2 ganglioside activator                    
                                               IL1RN     Interleukin 1 receptor antagonist            
                                               LILRB4    Leukocyte immunoglobulin like receptor B4    
                                               LIPA      Lipase A, lysosomal acid type                
                                               MRC1      Mannose receptor, C type 1                   
                                               MSR1      Macrophage scavenger receptor 1              
                                               PLA2G7    Phospholipase A2 group VII                   
                                               PLA2G15   Phospholipase A2 group XV                    
                                               SIGLEC1   Sialic acid‐binding Ig‐like lectin 1         
                                               SLC38A6   Solute carrier family 38 member 6            
  M1‐like                                      CCL2      C‐C motif chemokine ligand 2                 (Hill et al. [2014](#phy213183-bib-0012){ref-type="ref"})
                                               TNF       Tumor necrosis factor                        
                                               IL8       Interleukin 8                                
                                               COX20     COX20 cytochrome c oxidase assembly factor   
                                               IL6       Interleukin 6                                
                                               IL1B      Interleukin 1 beta                           
                                               ITGAX     Integrin subunit alpha X                     
                                               TLR4      Toll‐like receptor 4                         
                                               CCR2      C‐C motif chemokine receptor 2               
                                               IL1RN     Interleukin 1 receptor antagonist            
  M2‐like                                      IL10      Interleukin 10                               (Hill et al. [2014](#phy213183-bib-0012){ref-type="ref"})
                                               MRC1      Mannose receptor, C type 1                   
                                               TGFB1     Transforming growth factor beta 1            
                                               CCL18     C‐C motif chemokine ligand 18                
                                               CD163     CD163 molecule                               
                                               ITGB5     Integrin subunit beta 5                      

Ma; Macrophage markers.
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Multivariate normality was determined by the Shapiro--Wilk test and multicollinearity, homoscedasticity and extreme values were evaluated. We considered a *P *≤* *0.05 as statistically significant. R 3.1.1 was used for all statistical calculations.

Results {#phy213183-sec-0011}
=======

Group differences at baseline {#phy213183-sec-0012}
-----------------------------

The groups differed in several aspects at baseline (Table [1](#phy213183-tbl-0001){ref-type="table-wrap"}). Overweight, dysglycemic men had elevated levels of Hba1~c~, diastolic blood pressure, BMI, weight, fasting insulin and glucose levels, alanine transaminase (ALAT) and liver fat content, and lower GIR, compared to control participants (Table [1](#phy213183-tbl-0001){ref-type="table-wrap"}).

Response to 12 w exercise {#phy213183-sec-0013}
-------------------------

No weight change was observed in control men, whereas a reduction of 1.7 kg was observed in the dysglycemic men (Table [1](#phy213183-tbl-0001){ref-type="table-wrap"}). Both groups improved similarly in GIR and had reduced levels of liver fat content and plasma Fetuin‐A levels after the intervention (Table [1](#phy213183-tbl-0001){ref-type="table-wrap"}). The change in liver fat content was slightly different between the groups (Table [1](#phy213183-tbl-0001){ref-type="table-wrap"}). Plasma glucose levels increased slightly in controls and the change in plasma insulin levels differed between the groups (Table [1](#phy213183-tbl-0001){ref-type="table-wrap"}). The steady‐state insulin levels during the clamp were higher in the dysglycemic men after the intervention (Table [1](#phy213183-tbl-0001){ref-type="table-wrap"}). Plasma ALAT and aspartate transaminase (ASAT) levels were reduced in the dysglycemic men, also compared to the controls, after the 12 w intervention (Table [1](#phy213183-tbl-0001){ref-type="table-wrap"}). Plasma FFA levels were reduced in the control men after the intervention (Table [1](#phy213183-tbl-0001){ref-type="table-wrap"}), also compared to the dysglycemic men.

Plasma levels of fetuin‐A and FFAs, and their interaction, related to changes in insulin sensitivity in response to 12 weeks exercise {#phy213183-sec-0014}
-------------------------------------------------------------------------------------------------------------------------------------

Neither changes in plasma concentrations of fetuin‐A nor FFAs alone could predict changes in GIR in response to exercise (Table [2](#phy213183-tbl-0002){ref-type="table-wrap"}). However, the interaction between changes in plasma fetuin‐A and FFAs levels, representing the fetuin‐A‐fatty acid complex (Pal et al. [2012](#phy213183-bib-0029){ref-type="ref"}; Stefan and Haring [2013a](#phy213183-bib-0038){ref-type="ref"}) was a predictor of the change in GIR in response to exercise (Table [2](#phy213183-tbl-0002){ref-type="table-wrap"}). Similar observations were experienced using the product of fasting insulin and FFAs levels as a proxy for adipose tissue insulin resistance. No effects were observed for neither plasma fetuin‐A nor FFAs levels separately (data not shown), but a possible interaction effect was observed (Fig. [1](#phy213183-fig-0001){ref-type="fig"}B).

![Interaction between changes in plasma concentration of fetuin‐A and FFAs predicted changes in insulin sensitivity, adipose tissue insulin resistance, and adipose tissue macrophage‐related gene expression in response to exercise. Leverage plots are presented and show the unique effect of the interaction term in multiple regression models. The constrained model without the interaction term is shown as a horizontal line; the unconstrained model with the interaction term is shown as a slanted line with associated 95% confidence intervals as stapled lines. "Adjusted" refers to covariates in the model, which included subjects, due to repeated measurements, and group allocation. Black circles refer to control men and open triangles refer to dysglycemic men. The interaction effect between changes in plasma concentration of fetuin‐A and FFAs negatively predicted changes in the glucose infusion rate (A) and positively predicted changes in adipose tissue insulin resistance (B), adipose tissue macrophage‐related gene expression (C), and tended to predict the M1‐like macrophage phenotype (D) in response to 12 weeks of exercise intervention. FFAs; free fatty acids, AT‐IR; adipose tissue insulin resistance, indicated by the product of fasting plasma FFA and insulin levels. The full regression models are presented in Table [2](#phy213183-tbl-0002){ref-type="table-wrap"} and Table [6](#phy213183-tbl-0006){ref-type="table-wrap"}. The list of mRNA markers of macrophage‐related gene expressions in human adipose tissue is presented in Table [5](#phy213183-tbl-0005){ref-type="table-wrap"}. ":" is the Wilkinson‐Rogers symbolic description of factorial models for analysis of variance indicating an interaction.](PHY2-5-e13183-g001){#phy213183-fig-0001}

To test whether the observed relationships of FFA levels with GIR was specific for fetuin‐A, we investigated whether plasma concentrations of leptin and adiponectin would exhibit similar effects. There were no significant interaction effects between total or high molecular weight adiponectin and leptin with GIR or adipose tissue insulin resistance (data not shown).

Relationships between changes in plasma levels of fetuin‐A and FFAs, and their interaction, with changes in TLR and insulin receptor signaling pathways {#phy213183-sec-0015}
-------------------------------------------------------------------------------------------------------------------------------------------------------

We examined whether plasma concentration of fetuin‐A and FFAs, and their interaction, predicted changes in gene expression related to TLR and insulin receptor signaling in adipose tissue (Bessman et al. [1986](#phy213183-bib-0002){ref-type="ref"}; Pal et al. [2012](#phy213183-bib-0029){ref-type="ref"}). As a comparison, we also performed the analysis on the skeletal muscle.

In the adipose tissue, plasma fetuin‐A levels alone, as well as and the interaction between plasma fetuin‐A and FFAs levels, predicted changes in TLR‐signaling on the mRNA level (Table [3](#phy213183-tbl-0003){ref-type="table-wrap"}). The genes within the TLR and insulin receptor signaling‐related gene sets, which correlated with plasma FFA and fetuin‐A levels, and their interaction, are presented in Figure [2](#phy213183-fig-0002){ref-type="fig"}.

![Genes involved in adipose tissue TLR‐ and insulin receptor signaling correlated with changes in plasma concentration of fetuin‐A and FFAs. (A) Genes involved in adipose tissue TLR‐signaling correlated with plasma fetuin‐A levels. (B) Genes involved in adipose tissue insulin receptor signaling correlated with plasma fetuin‐A levels. (C) Genes involved in adipose tissue TLR‐signaling correlated with plasma FFAs levels. (D) Genes involved in adipose tissue insulin receptor signaling correlated with plasma FFAs levels. (E) Genes involved in adipose tissue TLR‐signaling correlated with the interaction between plasma fetuin‐A and FFAs levels. (F) Genes involved in adipose tissue insulin receptor signaling correlated with the interaction between plasma fetuin‐A and FFAs levels. The relationship between gene expression and plasma concentration of fetuin‐A and FFAs was modeled using linear regression. The genes predicted by the model were overlapped with KEGG, Reactome, and Biocarta pathways related to TLR‐ and insulin receptor signaling using a hypergeometric distribution, to test if the overlap was larger than expected by chance. The statistics and more details regarding the pathway analyses are presented in the legend to Table [3](#phy213183-tbl-0003){ref-type="table-wrap"} and the method section. Thinner lines indicate the strongest significance. ":" is the Wilkinson‐Rogers symbolic description of factorial models for analyses of variance indicating an interaction.](PHY2-5-e13183-g002){#phy213183-fig-0002}

Plasma concentration of fetuin‐A levels tended to predict TLR‐related gene expression in the skeletal muscle, and predicted insulin receptor signaling‐related gene expression (Table [4](#phy213183-tbl-0004){ref-type="table-wrap"}). The genes overlapping these pathways are presented in Figure [3](#phy213183-fig-0003){ref-type="fig"}. We observed no interaction effects between plasma concentration of fetuin‐A and FFAs on TLR and insulin receptor signaling in the skeletal muscle.

![Genes involved in skeletal muscle TLR‐ and insulin receptor signaling related to changes in plasma concentration of fetuin‐A and FFAs. (A) Genes involved in skeletal muscle TLR‐signaling correlated with plasma fetuin‐A levels. (B) Genes involved in skeletal muscle insulin receptor signaling correlated with plasma fetuin‐A levels. (C) Genes involved in skeletal muscle TLR‐signaling correlated with plasma FFAs levels. (D) Genes involved in skeletal muscle insulin receptor signaling correlated with plasma FFAs levels. (E) Genes involved in skeletal muscle TLR‐signaling correlated with the interaction between plasma concentration of fetuin‐A and FFAs. (F) Genes involved in skeletal muscle insulin receptor signaling correlated with the interaction between plasma concentration of fetuin‐A and FFAs. The relationship between gene expression and plasma fetuin‐A and FFAs levels was modeled using linear regression. The genes significantly predicted by the model were overlapped with KEGG, Reactome, and Biocarta pathways related to TLR‐ and insulin receptor signaling using a hypergeometric distribution, to test if the overlap was larger than expected by chance. The statistics and more details regarding the pathway analyses are presented in the legend to Table [4](#phy213183-tbl-0004){ref-type="table-wrap"}. Thinner lines indicate the strongest significance. ":" is the Wilkinson‐Rogers symbolic description of factorial models for analysis of variance indicating an interaction.](PHY2-5-e13183-g003){#phy213183-fig-0003}

Adipose tissue macrophages might be related to plasma concentrations of fetuin‐A and FFAs and their interaction {#phy213183-sec-0016}
---------------------------------------------------------------------------------------------------------------

Adipose tissue macrophages are important regulators of metabolism and inflammation, and proinflammatory "M1‐like" macrophages are known to induce insulin resistance (Hill et al. [2014](#phy213183-bib-0012){ref-type="ref"}). Thus, we tested if the change in markers of adipose tissue macrophages (Table [5](#phy213183-tbl-0005){ref-type="table-wrap"}) in response to exercise could be predicted by plasma concentrations of fetuin‐A and FFAs levels and their interaction. Plasma concentration of fetuin‐A alone, but not FFA levels, might predict adipose tissue macrophage‐related gene expression and the M1‐like phenotype (Table [6](#phy213183-tbl-0006){ref-type="table-wrap"} and Fig. [2](#phy213183-fig-0002){ref-type="fig"}). Moreover, interaction between plasma concentration of fetuin‐A and FFAs may also predict adipose tissue macrophage‐related gene expression and the M1‐like phenotype (Table [6](#phy213183-tbl-0006){ref-type="table-wrap"} and Fig. [2](#phy213183-fig-0002){ref-type="fig"}).

###### 

Relationships between plasma concentration of fetuin‐A and FFAs, and their interaction, with adipose tissue macrophage‐related gene expression

                                                  Macrophages       *P*     M1‐like          *P*     M2‐like           *P*
  ----------------------------------------------- ----------------- ------- ---------------- ------- ----------------- -------
  Fetuin‐A                                                                                                             
  (Intercept)                                     3.493 ± 4.981     0.491   0.830 ± 1.029    0.429   −0.182 ± 1.914    0.925
  Group[b](#phy213183-note-0018){ref-type="fn"}   −10.387 ± 5.824   0.089   −0.954 ± 1.203   0.437   −4.443 ± 2.238    0.060
  Fetuin‐A                                        30.328 ± 17.585   0.099   8.159 ± 3.633    0.036   4.052 ± 6.756     0.555
  FFAs                                                                                                                 
  (Intercept)                                     −1.265 ± 4.652    0.788   −0.546 ± 1.003   0.592   0.095 ± 1.626     0.954
  Group                                           −8.844 ± 6.371    0.180   −0.453 ± 1.374   0.745   −5.052 ± 2.226    0.034
  FFAs                                            1.463 ± 4.642     0.756   0.189 ± 1.001    0.852   2.131 ± 1.622     0.203
  Fetuin‐A\*FFAs                                                                                                       
  (Intercept)                                     3.290 ± 4.960     0.515   0.741 ± 1.051    0.490   0.527 ± 1.935     0.788
  Group                                           −9.170 ± 5.707    0.125   −0.678 ± 1.210   0.582   −4.816 ± 2.227    0.043
  Fetuin‐A                                        52.133 ± 19.027   0.013   12.268 ± 4.032   0.007   9.890 ± 7.423     0.199
  FFAs                                            8.139 ± 5.116     0.128   1.403 ± 1.084    0.211   4.115 ± 1.996     0.053
  Fetuin‐A:FFAs                                   94.096 ± 41.277   0.034   17.609 ± 8.748   0.059   26.964 ± 16.103   0.110

SE; standard error.

Dysglycemic, overweight participants (of which two participants did not donate adipose tissue biopsies). The list of mRNA markers used to analyze macrophage‐related gene expression in human adipose tissue is presented in Table [5](#phy213183-tbl-0005){ref-type="table-wrap"}. Plasma concentration of fetuin‐A and FFAs were log‐transformed to approximate multivariate normality.
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Discussion {#phy213183-sec-0017}
==========

Previous studies have mainly focused on the roles of myokines (Pedersen et al. [2007](#phy213183-bib-0031){ref-type="ref"}; Pedersen and Febbraio [2012](#phy213183-bib-0030){ref-type="ref"}) and adipokines (Gorgens et al. [2015](#phy213183-bib-0009){ref-type="ref"}; Stanford et al. [2015](#phy213183-bib-0037){ref-type="ref"}) to explain the health benefits of exercise. In this study, we demonstrate that long‐term physical exercise reduced plasma concentrations of the hepatokine fetuin‐A, suggesting that some of the health effects of exercise may be mediated via altered production and secretion of a hepatokine. Although it has been demonstrated that exercise may reduce plasma fetuin‐A concentrations (Malin et al. [2014](#phy213183-bib-0024){ref-type="ref"}), and that interaction of fetuin‐A and FFAs can induce TLR4‐associated insulin resistance (Pal et al. [2012](#phy213183-bib-0029){ref-type="ref"}; Stefan and Haring [2013a](#phy213183-bib-0038){ref-type="ref"}), we seem to be the first to demonstrate that changes in fetuin‐A and FFAs together may predict some of the benefits seen on insulin sensitivity after long‐term exercise. Moreover, we demonstrate that changes in circulating fetuin‐A together with FFAs may predict adipose tissue insulin resistance, gene expression concerning TLR‐signaling and macrophage‐related gene expression.

In accordance with the study of Malin and colleagues (Malin et al. [2014](#phy213183-bib-0024){ref-type="ref"}), we demonstrated that long‐term physical exercise reduced plasma concentrations of fetuin‐A. Interestingly, circulating fetuin‐A has also been shown to correlate strongly and positively with markers of early atherosclerosis (Rittig et al. [2009](#phy213183-bib-0033){ref-type="ref"}; Dogru et al. [2013](#phy213183-bib-0006){ref-type="ref"}) and components of the metabolic syndrome (Ix et al. [2006](#phy213183-bib-0014){ref-type="ref"}), independent of adiposity. Furthermore, circulating fetuin‐A levels correlated negatively with measures of insulin sensitivity (Mori et al. [2006](#phy213183-bib-0025){ref-type="ref"}; Ishibashi et al. [2010](#phy213183-bib-0013){ref-type="ref"}; Kantartzis et al. [2010](#phy213183-bib-0019){ref-type="ref"}; Xu et al. [2011](#phy213183-bib-0045){ref-type="ref"}; Kaess et al. [2012](#phy213183-bib-0018){ref-type="ref"}), and high circulating plasma fetuin‐A levels can be a strong predictor of T2DM incidence (Ix et al. [2008](#phy213183-bib-0015){ref-type="ref"}, [2012](#phy213183-bib-0016){ref-type="ref"}; Stefan et al. [2008](#phy213183-bib-0040){ref-type="ref"}; Sun et al. [2013](#phy213183-bib-0041){ref-type="ref"}). High plasma concentrations of fetuin‐A and FFAs have also been observed in insulin‐resistant individuals, and lower circulating fetuin‐A levels were observed after treatment with statins (Stefan and Haring [2013a](#phy213183-bib-0038){ref-type="ref"}). Thus, reducing the amount of circulating fetuin‐A by physical exercise might be important to prevent or treat T2DM and CVD.

Our data are compatible the idea that interaction between fetuin‐A and FFAs may represent the link between lipid metabolism and insulin resistance in humans in vivo. This is coherent with data indicating that interaction between fetuin‐A and FFAs was a predictor of insulin sensitivity (Stefan and Haring [2013a](#phy213183-bib-0038){ref-type="ref"}), and with studies on mice and different cell lines (Pal et al. [2012](#phy213183-bib-0029){ref-type="ref"}; Stefan and Haring [2013a](#phy213183-bib-0038){ref-type="ref"}). Fetuin‐A might also induce insulin resistance by itself, as well as together with FFAs, at least according to studies on overfeeding in humans (Samocha‐Bonet et al. [2014](#phy213183-bib-0036){ref-type="ref"}). This is also indicated by our gene expression results, revealing a link between fetuin‐A separately on skeletal muscle insulin receptor signaling and adipose tissue TLR receptor signaling. We hypothesize that less fetuin‐A is available after exercise, which might reduce the level of TLR4‐dependent insulin resistance in adipose tissue through lower plasma concentration of fetuin‐A and less interaction with FFAs. This might be reflected in increased insulin sensitivity following exercise. However, we cannot exclude that exercise alters plasma FFAs composition. Fetuin‐A binds several types of FFAs with different affinity, the strongest affinity being for saturated fatty acids such as palmitic acid (Pal et al. [2012](#phy213183-bib-0029){ref-type="ref"}; Stefan and Haring [2013a](#phy213183-bib-0038){ref-type="ref"}). Thus, alterations in plasma FFAs composition after exercise might thus influence the ability of fetuin‐A for inducing TLR4‐signaling.

The interaction between fetuin‐A and FFAs explained some of the variability in improving GIR in our study. GIR is mainly a measurement of skeletal muscle insulin sensitivity, although it is also markedly influenced by hepatic, and to a lesser degree, adipose tissue insulin sensitivity (DeFronzo et al. [1979](#phy213183-bib-0005){ref-type="ref"}). Measurements of endogenous glucose production, e.g., with glucose tracers would have strengthened our study, although hyperinsulinemia during clamp suppresses endogenous (hepatic) glucose production (DeFronzo et al. [1979](#phy213183-bib-0005){ref-type="ref"}; Reaven et al. [1983](#phy213183-bib-0032){ref-type="ref"}). However, we are unable to evaluate the degree of suppression as we did not measure hepatic insulin sensitivity directly, and 40 mU/m^2^ min^−1^ might not have been sufficient for insulin‐resistant participants. Some studies suggest that indices, such as the QUICKI (Katz et al. [2000](#phy213183-bib-0020){ref-type="ref"}) and MEC (Tajiri et al. [2011](#phy213183-bib-0042){ref-type="ref"}), which incorporates glucose and insulin levels during the clamp test in the formulas, might represent better measures of insulin sensitivity compared to GIR. However, GIR is the actual amount of glucose disappearing from blood without other variables in the calculations, thereby reducing sources of variation.

Another weakness in our study is the lack of measurement of FFAs levels during the clamp tests, which may provide an indication of adipose tissue insulin sensitivity. Instead, we calculated the product of fasting plasma concentrations of FFAs and insulin as a proxy. Taken together with the gene expression results, our study suggests that the interaction between fetuin‐A and FFAs relates to adipose tissue TLR‐signaling and adipose tissue insulin resistance. When looking for interaction between FFAs and other known cytokines on insulin sensitivity, such as adiponectin and leptin, we detected no such relationships. Moreover, we observed no interaction effect of fetuin‐A and FFAs on skeletal muscle TLR‐signaling. These results suggest a specific effect of fetuin‐A together with FFAs on insulin sensitivity related to the adipose tissue.

Adipose tissue macrophages may be important regulators of inflammation and metabolism (Hill et al. [2014](#phy213183-bib-0012){ref-type="ref"}). Our data and calculations based on results from previous studies (Capel et al. [2009](#phy213183-bib-0003){ref-type="ref"}; Ahlin et al. [2013](#phy213183-bib-0034){ref-type="ref"}; Hill et al. [2014](#phy213183-bib-0012){ref-type="ref"}), may suggest a relationship between plasma fetuin‐A and FFAs and adipose tissue macrophages. Fetuin‐A may promote inflammatory cytokine expression in monocytes and adipocytes, and may repress production of the insulin‐sensitizing adipokine adiponectin (Hennige et al. [2008](#phy213183-bib-0011){ref-type="ref"}; Dasgupta et al. [2010](#phy213183-bib-0004){ref-type="ref"}). Future studies should extend analyses of the relationship between adipose tissue macrophages and fetuin‐A and FFAs.

Some data indicate that increased plasma FFAs levels increase hepatic fetuin‐A expression in the liver by increasing NF‐*κ*B activity (Dasgupta et al. [2010](#phy213183-bib-0004){ref-type="ref"}), whereas other data suggest that high plasma glucose levels increase hepatic fetuin‐A expression in the liver via activation of the ERK‐1--ERK‐2 signaling pathway (Takata et al. [2009](#phy213183-bib-0043){ref-type="ref"}). However, the mechanisms behind the link between physical exercise and circulating fetuin‐A levels remain unknown. A weakness of our study is that we do not have liver biopsies and hence we were unable to assess the expression of the fetuin‐A gene directly.

In conclusion, we show that long‐term exercise may increase insulin sensitivity by lowering plasma concentration levels of the hepatokine fetuin‐A, probably by interfering with adipose tissue. Future studies should focus on identifying novel exercise‐regulated hepatokines with effect on energy metabolism.
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